IP Library Granted Patent US 10,522,245
Granted Patent B2
US 10,522,245 · App. 15/356,972 · Granted Dec 31, 2019

Systems and methods for detecting infectious diseases

Inventors: Clarissa Lui (Menlo Park, CA); Elizabeth A. Holmes (Palo Alto, CA)
Assignee: Theranos IP Company, LLC
G16H10/40C12Q1/689C12Q1/6893C12Q1/6895C12Q1/70C12Q1/701C12Q1/703C12Q1/705C12Q1/706C12Q1/707G01N33/56911G01N33/56916G01N33/56938G01N33/56944G01N33/56983G01N33/56988G01N33/56994G01N35/10C12Q1/68C12Q1/6806C12Q1/6844C12Q2521/501C12Q2600/158C12Q2600/16G01N2035/00237G01N2333/11G01N2469/10G01N2469/20G06F19/3456G16H20/10G16H50/20Y02A50/58Y02A90/24Y02A90/26Y10T436/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,522,245
App. No.
15/356,972
Granted
Dec 31, 2019
Kind
B2
Abstract

Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (POS) location and may be tested at the POS location for multiple markers for multiple diseases, including upper and lower respiratory diseases. Samples may be tested for cytokines, or for inflammation indicators. Dilution of samples, or levels of detection, may be determined by the condition or past history of a subject. Test results may be obtained within a short amount of time after sample placement in a testing device, or within a short amount of time after being obtained from the subject. A prescription for treatment of a detected disorder may be provided, and may be filled, at the POS location. A bill may be automatically generated for the testing, or for the prescription, may be automatically sent to an insurance provider, and payment may be automatically obtained.

Claims (39)

1. A method of detecting a disease marker, comprising:

a) introducing a cartridge comprising at least two different types of samples into an automatic sample processing device, wherein one of said samples comprises a swab sample carried on a swab, wherein said automatic sample processing device comprises:

i) a sample handling system configured to transport at least a portion of one of said samples and being configured to transport an independently movable assay unit; and

ii) an optical detector;

b) contacting one of said samples, or a portion thereof, with a movable assay unit, or a reagent, or both, for the performance of an assay for the detection of a disease marker;

c) positioning one of said samples, or portion thereof, at a location suitable for detection of an optical signal from the sample or portion thereof by said optical detector;

d) detecting the presence of a disease marker; and

e) processing the other of said samples using said automatic sample processing device to perform a second assay to detect a second disease marker.

2. The method of claim 1 , wherein said swab is entirely contained in the cartridge.

3. The method of claim 2 , wherein said sample obtained using said swab was obtained by swabbing a mouth, a throat, a nasal passage, a vaginal area, or other body cavity of a subject.

4. The method of claim 1 , wherein one of said samples comprises a sample obtained using said swab, and another of said samples comprises a blood sample.

5. The method of claim 1 , wherein said sample has a volume of less than about 500 microliters.

6. The method of claim 4 , comprising performing two or more assays for the detection of disease markers, and detecting two or more disease markers in said samples, or in one or more portions thereof.

7. The method of claim 6 , comprising detecting the presence of a nucleic acid disease marker and a protein disease marker.

8. The method of claim 1 , wherein said disease marker is selected from a nucleic acid disease marker, a protein disease marker, a saccharide, a prostaglandin, a cytokine, histamine, a steroid, and a marker for inflammation.

9. The method of claim 6 , wherein said two or more disease markers are selected from a nucleic acid disease marker, a protein disease marker, a saccharide, a prostaglandin, a cytokine, histamine, a steroid, and a marker for inflammation.

10. The method of claim 1 , wherein said disease marker is a marker for inflammation selected from prostaglandins, tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), interleukin-8 (IL-8), interleukin-12 (IL-12), interferon gamma (IF-γ), bradykinin, complement system molecules, blood-clotting factors, C-reactive protein, erythrocyte sedimentation rate (ESR), white blood cell count, and morphological changes in blood and other cells.

11. The method of claim 1 , wherein the method is a point-of service method performed at a point-of-service location.

12. The method of claim 5 , wherein the method is a point-of service method performed at a point-of-service location.

13. The method of claim 1 , wherein the method may be performed in less than about 40 minutes.

14. The method of claim 4 , wherein the method may be performed in less than about 40 minutes.

15. A method of detecting a disease marker, comprising:

a) introducing a cartridge comprising at least two different types of samples into an automatic sample processing device, wherein one of said samples comprises a swab sample carried on a swab, wherein said automatic sample processing device comprises:

i) a sample handling system configured to transport at least a portion of one of said samples and being configured to transport an independently movable assay unit; and

ii) an optical detector;

b) contacting one of said samples, or a portion thereof, with a movable assay unit, or a reagent, or both, for the performance of an assay for the detection of a disease marker;

c) positioning one of said samples, or portion thereof, at a location suitable for detection of an optical signal from the sample or portion thereof by said optical detector;

d) detecting the presence of a disease marker; and

e) processing the other of said samples using said automatic sample processing device to perform a second assay to detect a second disease marker;

wherein said one of said samples comprises a blood sample.

16. A method of detecting a disease marker, comprising:

a) introducing a cartridge comprising at least two different types of samples into an automatic sample processing device, wherein one of said samples comprises a swab sample carried on a swab, wherein said automatic sample processing device comprises:

i) a sample handling system configured to transport at least a portion of one of said samples and being configured to transport an independently movable assay unit; and

ii) an optical detector;

b) contacting one of said samples, or a portion thereof, with a movable assay unit, or a reagent, or both, for the performance of an assay for the detection of a disease marker;

c) positioning one of said samples, or portion thereof, at a location suitable for detection of an optical signal from the sample or portion thereof by said optical detector;

d) detecting the presence of a disease marker; and

e) processing the other of said samples using said automatic sample processing device to perform a second assay to detect a second disease marker;

wherein said disease marker comprises a nucleic acid disease marker and said second disease marker comprise a protein disease marker.

Assignments (5)
CHANGE OF NAME Recorded Apr 3, 2020
From: THERANOS IP COMPANY, LLC
To: LABRADOR DIAGNOSTICS LLC
Reel/Frame 052313/0011 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2018
From: THERANOS, INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 045075/0310 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2017
From: THERANOS INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 044838/0909 →
SECURITY INTEREST Recorded Dec 12, 2017
From: THERANOS IP COMPANY, LLC
To: FORTRESS CREDIT CORP.
Reel/Frame 044839/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2016
From: LUI, CLARISSA; HOLMES, ELIZABETH A.
To: THERANOS, INC.
Reel/Frame 040653/0350 →
Continuity (7)
Division 14479241 · Sep 5, 2014
Provisional Application 61874976 · Sep 6, 2013
Provisional Application 61885462 · Oct 1, 2013
Provisional Application 62001039 · May 20, 2014
Provisional Application 62001053 · May 21, 2014
Provisional Application 62010382 · Jun 10, 2014
Related Publication 20170168051A1 · Jun 15, 2017
Cited By (3)
US 1,069,156 US 1,140,078 US 1,143,079